|Paired-like homeodomain 2|
PDB rendering based on 1yz8.
|RNA expression pattern|
This gene encodes a member of the RIEG/PITX homeobox family, which is in the bicoid class of homeodomain proteins. This protein acts as a transcription factor and regulates procollagen lysyl hydroxylase gene expression. This protein is involved in the development of the eye, tooth and abdominal organs. This protein acts as a transcriptional regulator involved in basal and hormone-regulated activity of prolactin. A similar protein in other vertebrates is involved in the determination of left-right asymmetry during development. Three transcript variants encoding distinct isoforms have been identified for this gene.
Pitx2 is responsible for the establishment of the left-right axis, the asymmetrical development of the heart, lungs, and spleen, twisting of the gut and stomach, as well as the development of the eyes. Once activated Pitx2 will be locally expressed in the left lateral mesoderm, tubular heart, and early gut which leads to the asymmetrical development of organs and looping of the gut. When Pitx2 is deleted, the irregular morphogenesis of organs results on the left hand side. Pitx2 is left-laterally expressed controlling the morphology of the left visceral organs. Expression of Pitx2 is controlled by an intronic enhancer ASE and Nodal. It appears that while Nodal controls cranial expression of Pitx2, ASE controls left – right expression of Pitx2, which leads to the asymmetrical development of the left sided visceral organs, such as the spleen and liver. Collectively, Pitx2 first acts to prevent the apoptosis of the extraocular muscles followed by acting as the myogenic programmer of the extraocular muscle cells. There have also been studies showing different isoforms of the transcription factor: Pitx2a, Pitx2b, and Pitx2c, each with distinct and non-overlapping functions.
Pitx2 plays a role in limb myogenesis. Pitx2 can determine the development and activation of the MyoD gene (the gene responsible for skeletal myogenesis). Studies have shown that expression of Pitx2 happens before MyoD is expressed in muscles. Further studies show that Pitx2 is directly recruited to act on the MyoD core enhancer and thus, directing the expression of the MyoD gene. Pitx 2 is in a parallel pathway with Myf5 and Myf6, as both paths effect expression of MyoD. However, in the absence of the parallel pathway, Pitx2 can continue activating MyoD genes. The expression of Pitx2 saves MyoD gene expression and keeps expressing this gene for limb myogenesis. Yet, the Pitx 2 pathway is PAX3 dependent and requires this gene to enact limb myogenesis. Studies support this finding as in the absence of PAX3, there is Pitx2 expression deficit and thus, MyoD does not express itself in limb myogenesis. The Pitx2 gene is thus shown to be downstream of Pax3 and serve as an intermediate between Pax3 and MyoD. In conclusion, Pitx2 plays an integral role in limb myogenesis.
Pitx2 is overexpressed in many cancers. For example, thyroid, ovarian, and colon cancer all have higher levels of Pitx2 compared to noncancerous tissues. Scientists speculate that cancer cells improperly turn on Pitx2, leading to uncontrolled cell proliferation. This is consistent with the role of Pitx2 in regulating the growth-regulating genes cyclin D2, cyclin D1, and C-Myc.
In renal cancer, Pitx2 regulates expression of ABCB1, a multidrug transporter, by binding to the promoter region of ABCB1. Increased expression of Pitx2 in renal cancer cells is associated with increased expression of ABCB1. Thus, renal cancer cells that overexpress ABCB1 have a greater resistance to chemotherapeutic agents. In experiments where Pitx2 expression was decreased, renal cancer cells had decreased cell proliferation and greater susceptibility to doxorubicin treatment, which is consistent with other results.
In human esophageal squamous cell carcinoma (ESCC), Pitx2 is overexpressed compared to normal esophageal squamous cells. In addition, greater expression of Pitx2 is positively correlated with clinical aggressiveness of ESCC. Also, ESCC patients with high Pitx2 expression did not respond as well to definitive chemoradiotherapy (CRT) compared to ESCC patients with low Pitx2 expression. Thus, physicians may be able to use Pitx2 expression to predict how ESCC patients will respond to cancer treatment.
Mutations in this gene are associated with Axenfeld-Rieger syndrome (ARS), iridogoniodysgenesis syndrome (IGDS), and sporadic cases of Peters anomaly. This protein plays a role in the terminal differentiation of somatotroph and lactotroph cell phenotypes.
- Arakawa H, Nakamura T, Zhadanov AB, Fidanza V, Yano T, Bullrich F, Shimizu M, Blechman J, Mazo A, Canaani E, Croce CM (May 1998). "Identification and characterization of the ARP1 gene, a target for the human acute leukemia ALL1 gene". Proc Natl Acad Sci U S A 95 (8): 4573–8. doi:10.1073/pnas.95.8.4573. PMC 22531. PMID 9539779.
- Heon E, Sheth BP, Kalenak JW, Sunden SL, Streb LM, Taylor CM, Alward WL, Sheffield VC, Stone EM (Dec 1995). "Linkage of autosomal dominant iris hypoplasia to the region of the Rieger syndrome locus (4q25)". Hum Mol Genet 4 (8): 1435–9. doi:10.1093/hmg/4.8.1435. PMID 7581385.
- "Entrez Gene: PITX2 paired-like homeodomain transcription factor 2".
- Campione M, Steinbeisser H, Schweickert A, Deissler K, van Bebber F, Lowe LA, Nowotschin S, Viebahn C, Haffter P, Kuehn MR, Blum M (March 1999). "The homeobox gene Pitx2: mediator of asymmetric left-right signaling in vertebrate heart and gut looping". Development 126 (6): 1225–34. PMID 10021341.
- Shiratori H, Yashiro K, Shen MM, Hamada H (August 2006). "Conserved regulation and role of Pitx2 in situs-specific morphogenesis of visceral organs". Development 133 (15): 3015–25. doi:10.1242/dev.02470. PMID 16835440.
- Zacharias AL, Lewandoski M, Rudnicki MA, Gage PJ (January 2011). "Pitx2 is an upstream activator of extraocular myogenesis and survival". Dev. Biol. 349 (2): 395–405. doi:10.1016/j.ydbio.2010.10.028. PMC 3019256. PMID 21035439.
- Essner JJ, Branford WW, Zhang J, Yost HJ (March 2000). "Mesendoderm and left-right brain, heart and gut development are differentially regulated by pitx2 isoforms". Development 127 (5): 1081–93. PMID 10662647.
- L'Honoré, Aurore; Jean-François Ouimette,Jacques Marisol, Jacques Marisol (November 2010). "Pitx2 defines alternate pathways acting through MyoD during limb and somitic myogenesis". Development 137 (22): 3847. doi:10.1242/dev.053421. PMID 20978076.
- Huang Y, Guigon CJ, Fan J, et al. Pituitary homeobox 2 (PITX2) promotes thyroid carcinogenesis by activation of cycle D2" Cell Cycle 2010;9:1333-41.
- Fung FK, Chan DW, Liu VW, et al. Increased expression of PITC2 transcription factor contributes to ovarian cancer progression. Plos One 2012;7:e37076.
- Hirose H, Ishii H, Mimori K, et al. The significance of PITX2 overexpression in human colorectal cancer. Ann Surg Oncol 2011;18:3005-12.
- Kioussi C, Briata P, Baek SH, et al. Identification of a Wnt/Dvl/beta-Catenin --> Pitx2 pathway mediating cell-type-specific proliferation during development" Cell 2002; 111: 673– 685.
- Baek SH, Kioussi C, Briata P, et al. Regulated subset of G1 growth-control genes in response to derepression by the Wnt pathway" Proc Natl Acad Sci U S A 2003;100(6) 3245-3250.
- Lee W, Chakraborty PK, Thevenod F. Pituitary homeobox 2 (PITX2) protects renal cancer cell lines against doxorubicin toxicity by transcriptional activation of the multidrug transporter ABCB1" International Journal of Cancer 2013; 1-12
- Zhang J, Tong, Z, Yang L, et al. PITX2: A promising predictive biomarker of patients’ prognosis and chemoradioresistance in esophageal squamous cell carcinoma" International Journal of Cancer 2013;132:2567-2577.
- Franco D, Campione M (2003). "The role of Pitx2 during cardiac development. Linking left-right signaling and congenital heart diseases". Trends Cardiovasc. Med. 13 (4): 157–63. doi:10.1016/S1050-1738(03)00039-2. PMID 12732450.
- Hjalt TA, Semina EV (2007). "Current molecular understanding of Axenfeld-Rieger syndrome". Expert Reviews in Molecular Medicine 7 (25): 1–17. doi:10.1017/S1462399405010082. PMID 16274491.
- Murray JC, Bennett SR, Kwitek AE, et al. (1993). "Linkage of Rieger syndrome to the region of the epidermal growth factor gene on chromosome 4". Nat. Genet. 2 (1): 46–9. doi:10.1038/ng0992-46. PMID 1303248.
- Walter MA, Mirzayans F, Mears AJ, et al. (1996). "Autosomal-dominant iridogoniodysgenesis and Axenfeld-Rieger syndrome are genetically distinct". Ophthalmology 103 (11): 1907–15. PMID 8942889.
- Semina EV, Reiter R, Leysens NJ, et al. (1997). "Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome". Nat. Genet. 14 (4): 392–9. doi:10.1038/ng1296-392. PMID 8944018.
- Alward WL, Semina EV, Kalenak JW, et al. (1998). "Autosomal dominant iris hypoplasia is caused by a mutation in the Rieger syndrome (RIEG/PITX2) gene". Am. J. Ophthalmol. 125 (1): 98–100. doi:10.1016/S0002-9394(99)80242-6. PMID 9437321.
- Kulak SC, Kozlowski K, Semina EV, et al. (1999). "Mutation in the RIEG1 gene in patients with iridogoniodysgenesis syndrome". Hum. Mol. Genet. 7 (7): 1113–7. doi:10.1093/hmg/7.7.1113. PMID 9618168.
- Amendt BA, Sutherland LB, Semina EV, Russo AF (1998). "The molecular basis of Rieger syndrome. Analysis of Pitx2 homeodomain protein activities". J. Biol. Chem. 273 (32): 20066–72. doi:10.1074/jbc.273.32.20066. PMID 9685346.
- Yoshioka H, Meno C, Koshiba K, et al. (1998). "Pitx2, a bicoid-type homeobox gene, is involved in a lefty-signaling pathway in determination of left-right asymmetry". Cell 94 (3): 299–305. doi:10.1016/S0092-8674(00)81473-7. PMID 9708732.
- Doward W, Perveen R, Lloyd IC, et al. (1999). "A mutation in the RIEG1 gene associated with Peters' anomaly". J. Med. Genet. 36 (2): 152–5. doi:10.1136/jmg.36.2.152. PMC 1734311. PMID 10051017.
- Pellegrini-Bouiller I, Manrique C, Gunz G, et al. (1999). "Expression of the members of the Ptx family of transcription factors in human pituitary adenomas". J. Clin. Endocrinol. Metab. 84 (6): 2212–20. doi:10.1210/jc.84.6.2212. PMID 10372733.
- Hjalt TA, Amendt BA, Murray JC (2001). "Pitx2 Regulates Procollagen Lysyl Hydroxylase (Plod) Gene Expression: Implications for the Pathology of Rieger Syndrome". J. Cell Biol. 152 (3): 545–52. doi:10.1083/jcb.152.3.545. PMC 2196000. PMID 11157981.
- Priston M, Kozlowski K, Gill D, et al. (2001). "Functional analyses of two newly identified PITX2 mutants reveal a novel molecular mechanism for Axenfeld-Rieger syndrome". Hum. Mol. Genet. 10 (16): 1631–8. doi:10.1093/hmg/10.16.1631. PMID 11487566.
- Green PD, Hjalt TA, Kirk DE, et al. (2002). "Antagonistic regulation of Dlx2 expression by PITX2 and Msx2: implications for tooth development". Gene Expr. 9 (6): 265–81. PMID 11763998.
- Vincent AL, Billingsley G, Buys Y, et al. (2002). "Digenic Inheritance of Early-Onset Glaucoma: CYP1B1, a Potential Modifier Gene". Am. J. Hum. Genet. 70 (2): 448–60. doi:10.1086/338709. PMC 384919. PMID 11774072.
- Borges AS, Susanna R, Carani JC, et al. (2002). "Genetic analysis of PITX2 and FOXC1 in Rieger Syndrome patients from Brazil". J. Glaucoma 11 (1): 51–6. doi:10.1097/00061198-200202000-00010. PMID 11821690.
- Cox CJ, Espinoza HM, McWilliams B, et al. (2002). "Differential regulation of gene expression by PITX2 isoforms". J. Biol. Chem. 277 (28): 25001–10. doi:10.1074/jbc.M201737200. PMID 11948188.
- Quentien MH, Pitoia F, Gunz G, et al. (2002). "Regulation of prolactin, GH, and Pit-1 gene expression in anterior pituitary by Pitx2: An approach using Pitx2 mutants". Endocrinology 143 (8): 2839–51. doi:10.1210/en.143.8.2839. PMID 12130547.